Dissociated glucocorticoid receptor ligands

Current Opinion in Investigational Drugs

Volumn 5, Issue 5, 2004, Pages 524-528

  Schäcke, Heike ^a   Rehwinkel, Hartmut ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Autoimmune disorders; Glucocorticoid response elements; Glucocorticoids; GRIP1

Indexed keywords

ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IMMUNOSUPPRESSIVE AGENT; LIGAND;

ANIMAL; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMISTRY, PHARMACEUTICAL; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIGANDS; RECEPTORS, GLUCOCORTICOID;

EID: 3342946032     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Hench PS, Kendall EC, Slocumb CH, Polley HF: Proc Staff Meet Mayo Clin (1949) 24:181.
2. Schäcke H, Döcke WD, Asadullah K: Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther (2002) 96(1):23-43.
3. Ortonne JP: Clinical potential of topical corticosteroids. Drugs (1988) 36(Suppl 5):38-42.
4. Sterry W, Asadullah K: Topical glucocorticoid therapy in dermatology. In: Recent Advances in Glucocorticoids Receptor Action. Cato A, Schäcke H, Asadullah K (Eds), Springer, Berlin, Germany (2002):39-54.
5. Barnes PJ, Pedersen S, Busse WW: Efficacy of inhaled corticosteroids: An update. Am J Respir Crit Care Med (1998) 157(3 Pt 2):S1-S53.
6. Belvisi M, Hele D: Soft steroids: A new approach to the treatment of inflammatory airway diseases. Pulm Pharmacol Ther (2003) 16(6):321-325.
7. Barton BE, Jakway JP, Smith SR, Siegel MI: Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol (1991) 13(3):251-261.
8. O'Connell EJ: Review of the unique properties of budesonide. Clin Ther (2003) 25(Suppl C):C42-C60.
9. Welker P, Lippert U, Nürnberg W, Krüger-Krasagakes S, Möller A, Czarnetzki BM: Glucocorticoid-induced modulation of cytokine secretion from normal and leukemic human myelomonocytic cells. Int Arch Allergy Immunol (1996) 109(2):110-115.
10. Günther C, Kecskes A, Staks T, Täuber U. Percutaneous absorption of methylprednisolone aceponate following topical application of Advantan lotion on intact, inflamed and stripped skin of male volunteers. Skin Pharmacol Appl Skin Physiol (1998) 11(1):35-42.
11. Wärnmark A, Treuter E, Wright AP, Gustafsson J-A: Activation functions 1 and 2 of nuclear receptors: Molecular strategies for transcriptional activation. Mol Endocrinol (2003) 17(10):1901-1909.
12. Lefstin JA, Yamamoto KR: Allosteric effects of DNA on transcriptional regulators. Nature (1998) 392(6679):885-888.
13. Heck S, Kullmann M, Gast A, Ponta H, Rahmsdorf HJ, Herrlich P, Cato ACB: A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription of AP-1. EMBO J (1994) 13(17):4087-4095.
14. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schutz G: DNA binding of the glucocorticoid receptor is not essential for survival. Cell (1998) 93(4):531-541.
15. Rogatsky I, Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq CM, Darimont BD, Garabedian MJ, Yamamoto KR: Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proc Natl Acad Sci USA (2003) 100(24):13845-13850.
16. Cato AC, Wade E: Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays (1996) 18(5):371-378.
17. Barnes PJ: Molecular mechanisms of corticosteroids in allergic diseases. Allergy (2001) 56(10):928-936.
18. Adcock IM, Caramori G: Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol (2001) 79(4):376-384.
19. Karin M, Yamamoto Y, Wang QM: The IKK NF-κB system: A treasure trove for drug development. Nat Rev Drug Discov (2004) 3(1):17-26.
20. Ito K, Barnes PJ, Adcock IM: Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1β-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol (2000) 20(18):6891-6903.
21. Ito K, Jazrawi E, Cosio B, Barnes PJ, Adcock IM: p65-activated histone acetyltransferase activity is repressed by glucocorticoids: Mifepristone fails to recruit HDAC2 to the p65-HAT complex. J Biol Chem (2001) 276(32):30208-30215.
22. Vanden Berghe W, De Bosscher K, Vermeulen L, De Wlde G, Haegeman G: In: Proceedings of the ESRF Workshop: Recent Advances in Glucocorticoid Receptor Action. Cato A, Schäcke H, Asadullah K (Eds), Springer, Berlin, Germany (2002):233-278.
23. Nissen RM, Yamamoto KR: The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev (2000) 14(18):2314-2329.
24. Caelles C, González-Sancho JM, Munoz A: Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev (1997) 11(24):3351-3364.
25. Bruna A, Nicolas M, Munoz A, Kyriakis JM, Caelles C: Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids. EMBO J (2003) 22(22):6035-6044.
26. Kassel O, Sancono A, Krätzschmar J, Kreft B, Stassen M, Cato AC: Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J (2001) 20(24):7108-7116.
27. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR: Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol (2002) 22(22):7802-7811.
28. McKenna NJ, O'Malley BW: Minireview: Nuclear receptor coactivators - an update. Endocrinology (2002) 143(7):2461-2465.
29. Khan OY, Nawaz Z: Nuclear hormone receptor co-regulators. Curr Opin Drug Discovery Dev (2003) 6(5):692-701.
30. Robyr D, Wolffe AP, Wahli W: Nuclear hormone receptor coregulators in action: Diversity of shared tasks. Mol Endocrinol (2000) 14(3):329-347.
31. Aranda A, Pascual A: Nuclear hormone receptors and gene expression. Physiol Rev (2001) 81(3):1269-1304.
32. Xu J, O'Malley BW: Molecular mechanisms and cellular biology of the steroid receptor coactivator (SRC) family in steroid receptor function. Rev Endocrine Metab Disorders (2002) 3(3):185-192.
33. Reichardt HM, Tuckermann JP, Göttlicher M, Vujic M, Weih F, Angel P, Herrlich P, Schütz G: Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J (2001) 20(24):7168-7173.
34. Miner JN: Designer glucocorticoids. Biochem Pharmacol (2002) 64(3):355-361.
35. Buckbinder L, Robinson RP: The glucocorticoid receptor: Molecular mechanism and new therapeutic opportunities. Curr Drug Targets -Inflamm Allergy (2002) 1(2):127-136.
36. Doggrell S: Is AL-438 likely to have fewer side effects than the glucocorticoids? Expert Opin Invest Drugs (2003) 12(7):1227- 1229.
37. Coghlan MJ, Elmore SW, Kym PR, Kort ME: The pursuit of differentiated ligands for the glucocorticoid receptor. Curr Top Med Chem (2003) 3(14):1617-1635.
38. Högger P: Current concepts for optimizing the therapeutic index of glucocorticoid receptor ligands for oral inhalative use: Basic considerations and clinical reality. Curr Med Chem (2003) 2:395-408.
39. Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer H, Resche-Rigon M: Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol (1997) 11(9):1245-1255.
40. Belvisi MG, Wicks Sl, Battram CH, Bottoms SEW, Redford JE, Woodman P, Brown TJ, Webber SE, Foster ML: Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol (2001) 166(3):1975-1982.
41. Tanigawa K, Tanaka K, Nagase H, Miyake H, Kiniwa M, Ikizawa K: Cell type-dependent divergence of transactivation by glucocorticoid receptor ligand. Biol Pharm Bull (2002) 25(12):1619-1622.
42. Miner JN, Tyree C, Hu J, Berger E, Marschke K, Nakane M, Coghlan MJ, Clemm D, Lane B, Rosen J: A nonsteroidal glucocorticoid receptor antagonist. Mol Endocrinol (2003) 17(1):117-127.
43. Coghlan MJ, Jacobson PB, Lane B, Nakane M, Lin CW, Elmore SW, Kym PR, Luly JR, Carter GW, Turner R, Tyree CM et al: A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol (2003) 17(5):860-869.
44. Schäcke H, Schottelius A, Döcke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, Asadullah K: Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA (2004) 101(1):227-232.
45. Kym PR, Kort ME, Coghlan MJ, Moore JL, Tang R, Ratajczyk JD, Larson DP, Elmore SW, Pratt JK, Stashko MA, Falls HD et al: Nonsteroidal selective glucocorticoid modulators: The effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H- [1]benzopyrano[3,4-f]quinolines. J Med Chem (2003) 46(6):1016-1030.
46. Ku Y-Y, Grieme T, Raje P, Sharma P, Morton HE, Rozema M, King SA: A practical and scaleable synthesis of A-224817.0, a novel nonsteroidal ligand for the glucocorticoid receptor. J Org Chem (2003) 68(8):3238- 3240.
47. Rogatsky I, Zarember KA, Yamamoto KR: Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J (2001) 20(21):6071-6083.
48. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, Rudolph D, Schütz G, Yoon C, Puigserver P, Spiegelman B, Montminy M: CREB regulates hepatic gluconeogenesis through coactivator PGC-1. Nature (2001) 413(6852):179-183.
49. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK, Newgard CB, Spiegelman BM: Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature (2001) 413(6852):131-138.
50. Rogatzky I: Drug discovery for inflammatory diseases. Expert Opin Biol Ther (2003) 3(6):1001-1004.
51. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, Lambert MH et al: Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell (2002) 110(1):93-105.
52. Necela BM, Cidlowski JA: Crystallization of the human glucocorticoid receptor ligand binding domain: A step towards selective glucocorticoids. Trends Pharmacol Sci (2003) 24(2):58-61.
53. Kauppi B, Jakob C, Färnegardh M, Yang J, Ahola H, Alarcon M, Calles K, Engström O, Harlan J, Muchmore S, Ramqvist AK et al: The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem (2003) 278(25):22748-22754.
54. Adams M, Meijer OC, Wang J, Bhargava A, Pearce D: Homodimerization of the glucocorticoid receptor is not essential for response element binding: Activation of the phenylethanolamine N-methyltransferase gene by dimerization-defective mutants. Mol Endocrinol (2003) 17(12):2583-2592.
55. SCHERING AG (Jaroch S, Lehmann M, Schmees N, Berger M, Rehwinkel H, Krolikiewicz K, Skuballa W, Schäcke H, Schottelius A): Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents. WO-03082827 (2003).
56. SCHERING AG (Jaroch S, Lehmann M, Schmees N, Buchmann B, Rehwinkel H, Droescher P, Skuballa W, Krolikiewicz K, Hennekes H, Schäcke H, Schottelius A): Non-steroidal inflammation inhibitors. WO-00210143 (2002).
57. PFIZER INC (Liu KK-C, Morgan BP, Robinson RP Jr): Glucocorticoid receptor modulators. EP-01201660 (2002).
58. PFIZER INC (Liu KK-C, Morgan BP, Robinson RP Jr.): Glucocorticoid receptor modulators. EP-01201649 (2002).
59. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Thomson D, Kuzmich D, Kirrane TM, Proudfoot JR, Razavi H): 4-(Aryl or heteroaryl)-2-butylamine derivatives and their use as glucocorticoid ligands. WO-03104195 (2003).
60. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Thomson D, Kuzmich D, Kirrane TM, Proudfoot JR): Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof. WO-03101932 (2003).
61. BOEHRINGER INGELHEIm PHARMACEUTICALS INC (Bekkali Y, Betageri R, Gilmore TA, Cardozo MG, Kirrane TM, Kuzmich D, Proudfoot JR, Takahashi H, Thomson D, Wang J, Zindell R, Harcken CHJJ, Riether D): Glucococorticoid mimetics, methods of making them, pharmaceutical composition, and uses thereof. WO-03082280 (2003).
62. BOEHRINGER INGELHEIM PHARMACEUTICALSI NC (Bekkali Y, Cardozo MG, Kirrane TM, Kuzmich D, Proudfoot JR, Takahashi H, Thomson D, Wang J, Zindell R, Harcken CHJJ, Razavi H): Glucocorticoid mimetics, methods of making them pharmaceutical compositions and there uses thereof. WO-03082787 (2003).
63. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Betageri R, Thomson D, Zhang Y, Zindell RM): Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof. WO-03059899 (2003).
64. BOEHRINGER INGELHEIM PHARMA (Thomson DS, Jennewein HM, Pairet M, Kalkbrenner F, Kreideweiss S): Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side-effect. WO-02049634 (2002).
65. MERCK & CO INC (Ali A, Balkovec JM, Graham DW, Thompson CF, Quraishi N): 1H-Benzo[f] indazol-5-yl derivatives as selective glucocorticoid receptor modulators. WO-03086294 (2003).